Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.

Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T.

Cells. 2019 Apr 6;8(4). pii: E321. doi: 10.3390/cells8040321. Review.

2.

Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy.

Roviello G, Corona SP, Aieta M, Roudi R.

Cancer Biother Radiopharm. 2019 Apr;34(3):141-146. doi: 10.1089/cbr.2018.2702. Epub 2019 Jan 8.

PMID:
30620216
3.

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Roviello G, Corona SP, Multari AG, Paganini G, Chiriacò G, Conca R, Petrioli R, Generali D, Rosellini P, Aieta M.

Oncotarget. 2018 Apr 27;9(32):22332-22339. doi: 10.18632/oncotarget.24900. eCollection 2018 Apr 27.

4.

Lenvatinib for the treatment of renal cell carcinoma.

Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N.

Expert Opin Investig Drugs. 2018 May;27(5):507-512. doi: 10.1080/13543784.2018.1472235. Epub 2018 May 14. Review.

PMID:
29718721
5.

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.

Corona SP, Generali D.

Drug Des Devel Ther. 2018 Feb 16;12:321-330. doi: 10.2147/DDDT.S137783. eCollection 2018. Review.

6.

Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.

Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A.

J Cancer Res Clin Oncol. 2018 Mar;144(3):601-606. doi: 10.1007/s00432-017-2574-4. Epub 2018 Jan 17.

PMID:
29344722
7.

Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

Corona SP, Roviello G, Strina C, Milani M, Allevi G, Aguggini S, Zanoni D, Generali D.

Future Oncol. 2017 Nov;13(27):2473-2477. doi: 10.2217/fon-2017-0272. Epub 2017 Nov 10.

PMID:
29121807
8.

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.

Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, Generali D, Roviello G.

Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3.

9.

Advances in systemic therapy for malignant mesothelioma: future perspectives.

Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D.

Future Oncol. 2017 Oct;13(23):2083-2101. doi: 10.2217/fon-2017-0224. Epub 2017 Oct 6. Review.

PMID:
28984470
10.
11.

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer.

Roviello G, Corona SP, Bonetta A, Cappelletti MR, Generali D.

Onco Targets Ther. 2017 Jul 31;10:3811-3815. doi: 10.2147/OTT.S143020. eCollection 2017.

12.

Isolated Testicular Metastasis from Prostate Cancer.

Bonetta A, Generali D, Corona SP, Cancarini G, Brenna SG, Pacifico C, Roviello G.

Am J Case Rep. 2017 Aug 14;18:887-889.

13.

CDK4/6 inhibitors in HER2-positive breast cancer.

Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D.

Crit Rev Oncol Hematol. 2017 Apr;112:208-214. doi: 10.1016/j.critrevonc.2017.02.022. Epub 2017 Feb 24. Review.

PMID:
28325261

Supplemental Content

Loading ...
Support Center